The real-world analysis of adverse events with azacitidine: a pharmacovigilance study based on the FAERS and WHO-VigiAccess databases
This research not only confirms the widely acknowledged AEs linked to azacitidine but also uncovers several potentially new safety concerns noted in actual clinical practice. These results may offer important vigilance information for clinicians and pharmacists when addressing safety issues associated with azacitidine.
Authors
- Baiquan Zhang
- Zhaorui Wang (ORCID: https://orcid.org/0009-0007-1457-5437)
- Linlin Guo (ORCID: https://orcid.org/0009-0006-1045-7153)
- Yang Wang (ORCID: https://orcid.org/0000-0001-8639-4677)
- Juan Ding (ORCID: https://orcid.org/0000-0003-1943-870X)
- Youfu He (ORCID: https://orcid.org/0000-0003-4926-1706)
Institutions
- Innovation Cluster (Canada) (CA)
- Zhengzhou People's Hospital (CN)
- Guizhou Provincial People's Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-03-19
- DOI
- https://doi.org/10.3389/fphar.2025.1555838
- Citations
- 1
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 1.40